Aktienanalyse zu Vivani Medical Inc (VANI)VANIVivani Medical Inc

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its segments include the Biopharm Division and Neurostimulation Division. Its pipeline includes NPM-139, NPM-133, NPM-115 and OKV-119. NPM-139 is a six-month, semaglutide implant under development for the treatment of chronic weight management. NPM-115 is an exenatide-based implant candidate also under development for the treatment of chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed for once or twice-yearly administration of medication. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Vivani Medical Inc is not a good buy right now due to its current price of $1.09, which is significantly below the analyst price target of $4, but the company's financial performance is concerning. The company has reported consistent net losses, with a net income of -6,780,000 USD in Q1 2026 and a gross profit of 0 USD in Q4 2024, indicating ongoing financial struggles. Additionally, the RSI is at 30.041, suggesting the stock is oversold, but the overall trend is negative with a 1-year change of -27.57%. The main risk is the company's high debt levels, with total debt at 17,856,000 USD, which could hinder its ability to recover financially.